Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Monitor patients with chronic hepatitis B awaiting therapy or on therapy according to current practice guidelines
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Humanity and Health Medical Group
Hong Kong, China
Chair, Professor, and Co-Director
Liver Diseases & Transplant Centre
The Fifth Medical Centre of Chinese PLA General Hospital,
Manager, Editorial Operations
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians, pharmacists, registered nurses, and other healthcare providers who provide care for patients at risk of or diagnosed with HBV.
The goal of this activity is to improve clinicians’ competence in applying guideline-based care in the management of patients with hepatitis B, by addressing common mistakes identified through the Hep B Consult Tool.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-201-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 07, 2021, through October 06, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Listen to expert insights on the limitations of the current APASL recommendations for screening and surveilling patients with chronic hepatitis B for hepatocellular carcinoma.
Dr. Paul Y. Kwo discusses his take on the importance of universal screening of all patients with hepatitis B virus (HBV) for hepatitis delta virus (HDV), from Clinical Care Options (CCO)
Clinical Care Options (CCO) expert analysis by Dr. Nancy Reau on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta
Clinical Care Options (CCO) podcast with Dr. Nancy Reau on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta
Clinical Care Options (CCO) expert analysis by Dr. Stefan Zeuzem on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta